Sort
82,697 grants matching “vaccine development”
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
$1,089,350Moriya Tsuji · Columbia University Health Sciences · N01 · FY2024 · AI
Immunity to Pulmonary Infections
$1,089,245Catharine Bosio · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Long-lasting cocaine-metabolizing enzyme for cocaine addiction treatment
$1,088,896Chang-Guo Zhan · University Of Kentucky · R01 · FY2015 · DA
Entry and replication of positive-sense, RNA viruses
$1,088,811Joseph Marcotrigiano · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
Integrated polymer microfluidic device for multiplex diagnosis of viral infection
$1,088,801Robert G. Ulrich · Geneva Foundation · R01 · FY2011 · AI
Integrase
$1,088,800Stephen H Hughes · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
THE SEARCH FOR COVID-19 PREVENTION AND CURE: ADDRESSING THE CRITICAL ROLE OF INNATE/ADAPTIVE IMMUNITY BY INTEGRATING NOVEL INFORMATICS, TRANSLATIONAL TECHNOLOGIES, AND ONGOING CLINICAL TRIAL RESEARCH
$1,088,735Dan M Cooper · University Of California-Irvine · UL1 · FY2020 · TR
Oklahoma Center for Respiratory and Infectious Diseases
$1,088,733Lin Liu · Oklahoma State University Stillwater · P30 · FY2024 · GM
Combination Adjuvants to Activate Human Dendritic Cell Subsets and B Cells
$1,088,630Jacques F Banchereau · Jackson Laboratory · U01 · FY2019 · AI
Respiratory Virus Vaccine and Adjuvant Exploration - Equipment Supplement
$1,088,512Ralph S Baric · Univ Of North Carolina Chapel Hill · U01 · FY2020 · AI
Center of Excellence for High Throughput Proteogenomic Characterization
$1,088,100Steven A. Carr · Broad Institute, Inc. · U24 · FY2022 · CA
Cape Town Clinical Trials Unit (CT-CTU) for HIV/AIDS Prevention & Treatment
$1,088,081Robin Wood · University Of Cape Town · U01 · FY2011 · AI
Center of Excellence for High Throughput Proteogenomic Characterization
$1,088,025Steven A. Carr · Broad Institute, Inc. · U24 · FY2025 · CA
Preclinical evaluation of a trivalent Marburg vaccine
$1,087,854John Y Dong · Genphar, Inc. · U01 · FY2008 · AI
Antibody effector function in protection against HIV-1
$1,087,698Dennis R. Burton · Scripps Research Institute, The · R37 · FY2011 · AI
ADOLESCENT MEDICINE TRIAL NETWORK FOR HIV/AIDS
$1,087,542University Of Miami School Of Medicine · U01 · FY2001 · HD
Virtual Patient Cohorts to Illuminate Immunologic Drivers of Influenza Severity
$1,087,528Amber M Smith · University Of Tennessee Health Sci Ctr · R01 · FY2025 · AI
Persistent modulation of microbiota to enhance HIV vaccination
$1,086,868Nichole Rose Klatt · University Of Washington · R01 · FY2017 · AI
Vector Biological Studies in Leishmaniasis
$1,086,843David Sacks · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
Harvard Medical School Vaccine Clinical Trials Unit
$1,086,687Raphael Dolin · Beth Israel Deaconess Medical Center · UM1 · FY2013 · AI
Novel interventions for gammaherpesvirus infection and AIDS-Related Malignancies
$1,086,648Laurie T Krug · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Natural History of AIDS in Homosexual Men
$1,086,540University Of California Los Angeles · U01 · FY2001 · AI
Immunization against filamentous bacteriophages to prevent bacterial infection
$1,086,375Patrick R Secor · University Of Montana · R01 · FY2020 · AI
Assessment of metformin for restoration of immune homeostasis in HIV+ and HIV- individuals with a history of injection drug use
$1,086,368James J Kobie · University Of Alabama At Birmingham · R01 · FY2024 · DA
Oral Antiviral Prodrugs for Biodefense Initiative
$1,086,216John M Hilfinger · Tsrl, Inc. · U01 · FY2008 · AI